| Wang, Feng |
NCT05049681: Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell |
|
|
| Not yet recruiting | 3 | 234 | NA | Camrelizumab, SHR-1210, Apatinib | Feng Wang | Esophageal Cancer | 12/22 | 06/23 | | |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 472 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC |
|
|
| Recruiting | 3 | 176 | RoW | Experimental drug, CAP, Control Rx, FOLFIRI+BEV | Sun Yat-sen University | Metastatic Microsatellite-stable Colorectal Cancer | 01/26 | 01/27 | | |
NCT05737563: PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC |
|
|
| Recruiting | 3 | 380 | RoW | PD-1 Inhibitors, Irinotecan, Capecitabine tablets | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., Jiangsu HengRui Medicine Co., Ltd. | Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | 02/26 | 02/26 | | |
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 540 | RoW | Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab | Sun Yat-sen University | Gastric Cancer | 12/26 | 12/28 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
CAP 02, NCT03736863: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 147 | RoW | Apatinib+ SHR-1210（Camrelizumab）, Apatinib+ SHR-1316（Adebrelimab）, SHR-1316（Adebrelimab）+SHR-A2009 | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer | 06/21 | 12/25 | | |
NCT03387904: Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 120 | RoW | Anlotinib Plus Irinotecan, Irinotecan | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/21 | 12/22 | | |
NCT04514835: A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC |
|
|
| Not yet recruiting | 2 | 44 | RoW | Cisplatin+Capecitabine+Sintilimab | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 01/22 | 01/23 | | |
NCT04654403: Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer |
|
|
| Not yet recruiting | 2 | 337 | RoW | Camrelizumab, SHR-1210 | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer | 05/22 | 12/22 | | |
NCT04888403: Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Toripalimab+Nedaplatin+Albumin Paclitaxel | The First Affiliated Hospital of Zhengzhou University | Locally Advanced Esophageal Squamous Cell Carcinoma | 07/22 | 07/22 | | |
NCT04157140: Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC |
|
|
| Recruiting | 2 | 48 | RoW | Anlotinib, TACE+RFA | Jinglong Chen | Hepatocellular Carcinoma | 09/22 | 03/23 | | |
NCT04533490: A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 42 | NA | SHR-1210 | The First Affiliated Hospital of Zhengzhou University | Resectable Esophageal Squamous Cell Carcinoma | 10/22 | 10/23 | | |
NCT03766178: Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Nimotuzumab + SHR-1210 | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/22 | 09/23 | | |
NCT04984018: Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade |
|
|
| Not yet recruiting | 2 | 73 | NA | chidamide + camrelizumab | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/22 | 12/23 | | |
| Recruiting | 2 | 112 | RoW | Nimotuzumab, Sintilimab, Paclitaxel-albumin, Cisplatin | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer | 09/25 | 09/25 | | |
NCT05241899: A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer |
|
|
| Not yet recruiting | 2 | 56 | RoW | Fruquintinib + RC48 | The First Affiliated Hospital of Zhengzhou University | Gastric Cancer | 05/23 | 05/25 | | |
EASOAIPPGL, NCT05133349: A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial |
|
|
| Recruiting | 2 | 20 | RoW | Anlotinib | Nanjing First Hospital, Nanjing Medical University | Advanced or Metastatic Paraganglioma/ Pheochromocytoma | 09/23 | 12/23 | | |
SHR-1210-02, NCT03917966: The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC |
|
|
| Recruiting | 2 | 80 | RoW | SHR-1210+docetaxel+nedaplatin, SHR-1210+Apatinib | The First Affiliated Hospital of Zhengzhou University, Jiangsu HengRui Medicine Co., Ltd. | Locally Advanced Esophageal Squamous Cell Carcinoma | 10/23 | 10/24 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |
NCT03810339: Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors |
|
|
| Recruiting | 2 | 35 | RoW | Toripalimab | Sun Yat-sen University | Solid Tumor, Advanced Cancer | 01/24 | 01/24 | | |
NCT05738434: Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC |
|
|
| Recruiting | 2 | 188 | RoW | Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer by AJCC V8 Stage | 09/25 | 03/27 | | |
NCT06439550: Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC |
|
|
| Not yet recruiting | 2 | 42 | NA | Serplulimab, Trastuzumab, Oxaliplatin + Tegafur, SOX | The First Affiliated Hospital of Zhengzhou University | HER2-positive Gastric Cancer | 12/26 | 12/26 | | |
NCT05896787: Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) |
|
|
| Not yet recruiting | 2 | 45 | RoW | AK104, nab-paclitaxel, carboplatin, Candonilimab，Preoperative Chemotherapy | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 08/24 | 08/26 | | |
NCT06730373: First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) |
|
|
| Recruiting | 2 | 110 | RoW | Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin, Capecitabine, 5-FU, Cisplatin | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma | 12/26 | 12/27 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT04819971: Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC |
|
|
| Recruiting | 2 | 67 | RoW | Tirelizumab, Trastuzumab, Docetaxel, S1, Oxaliplatin | The First Affiliated Hospital of Zhengzhou University | Stomach Cancer | 12/25 | 12/25 | | |
NCT05024812: Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 1/2 | 64 | RoW | fruquintinib＋toripalimab + SOX | The First Affiliated Hospital of Zhengzhou University | Metastatic Gastric Cancer | 08/23 | 02/25 | | |
NCT05330065: A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion |
|
|
| Not yet recruiting | 1/2 | 55 | NA | bevacizumab and camrelizumab | The First Affiliated Hospital of Zhengzhou University | Malignant Pleural Effusion | 08/23 | 08/24 | | |
TQB2618-AK105-Ib-03, NCT05834543: Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 1/2 | 75 | RoW | TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin, Penpulimab injection, Paclitaxel, Cisplatin, TQB2618 injection, Penpulimab injection, TQB3617capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Esophageal Squamous Cell Carcinoma | 12/24 | 12/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 120 | RoW | Genakumab, Tislelizumab | GeneScience Pharmaceuticals Co., Ltd. | Malignant Solid Tumors | 06/24 | 03/25 | | |
BL-M17D1-102, NCT06500052: A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | BL-M17D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Solid Tumor | 08/26 | 08/26 | | |
NCT05043675: Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients |
|
|
| Recruiting | 1 | 6 | RoW | [18F]APN-1607, [18F]PBB3 | Nanjing First Hospital, Nanjing Medical University | Alzheimer Disease | 09/24 | 09/24 | | |
NCT06050239: Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer |
|
|
| Recruiting | 1 | 10 | RoW | 177Lu-PSMA-0057 | Nanjing First Hospital, Nanjing Medical University | Metastatic Prostate Cancer | 03/25 | 03/25 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
NCT05197673: Identifying Risks of COVID-19 Outbreaks in Work Settings and the Implications for Control Measures |
|
|
| Completed | N/A | 310 | RoW | Theory of planned behaviours (TPB) based intervention | Chinese University of Hong Kong | Intention to Get SARS-CoV-2 Vaccination, Intention to Get SARS-CoV-2 Antibody Test | 04/23 | 05/23 | | |
NCT05048810: Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma |
|
|
| Completed | N/A | 6 | RoW | 68Ga-DOTA-NT-20.3 | Nanjing First Hospital, Nanjing Medical University | Pancreatic Ductal Adenocarcinoma | 03/23 | 03/23 | | |
| Recruiting | N/A | 349 | RoW | CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy | Sun Yat-sen University, Guangzhou Burning Rock Dx Co., Ltd. | Colorectal Cancer | 07/28 | 07/28 | | |
NCT06054789: Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer |
|
|
| Recruiting | N/A | 8 | RoW | 68Ga-PSMA-33, 68Ga-PSMA-617 | Nanjing First Hospital, Nanjing Medical University | Prostate Cancer | 10/23 | 10/24 | | |
NCT05593224: The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Intracranial Atherosclerotic Stenosis |
|
|
| Not yet recruiting | N/A | 156 | RoW | Intracranial Stent (Tonbridge) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Atherosclerosis | 11/23 | 05/25 | | |
NCT05415995: A Trail of Drug-coated Balloon Treating Below The Knee Arterial Diseases |
|
|
| Recruiting | N/A | 202 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Artery Disease | 12/23 | 12/24 | | |
NCT05757505: The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis |
|
|
| Recruiting | N/A | 200 | RoW | Intracranial Stent (Tonbridge), Wingspan Stent System (Stryker Neurovascular) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Atherosclerosis | 01/25 | 12/25 | | |
NCT05719688: Evaluate the Safety and Efficacy of Thrombectomy System in the Intravascular Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | N/A | 200 | RoW | Mechanical thrombectomy | Suzhou Hengruihongyuan Medical Technology Co. LTD | Acute Ischemic Stroke | 12/23 | 12/24 | | |
NCT06438705: 99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors |
|
|
| Recruiting | N/A | 20 | RoW | SPECT-CT imaging | Nanjing First Hospital, Nanjing Medical University | Head and Neck Tumor, Lung Cancer, Pancreatic Cancer | 01/26 | 01/26 | | |
NCT06261762: Hard and Soft Tissue Dimensional Change After Consecutive Extractions and Unassisted Socket Healing in the Esthetic Zone |
|
|
| Not yet recruiting | N/A | 20 | NA | | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Wound Heal | 06/26 | 06/26 | | |
GENIUS, NCT04849325: IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease |
|
|
| Recruiting | N/A | 120 | RoW | Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titanâ„¢), Percutaneous Transluminal Angioplasty (PTA) Device | Biotyx Medical (Shenzhen) Co., Ltd. | Critical Limb Ischemia (CLI) | 04/24 | 10/24 | | |
| Recruiting | N/A | 30 | RoW | Recombinant Human Thyroid Stimulating Hormone | Nanjing First Hospital, Nanjing Medical University | DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C, Radiotherapy; Complications | 03/26 | 12/26 | | |
| Recruiting | N/A | 7 | RoW | prone position | Seventh Medical Center of PLA General Hospital, Gansu Provincial Maternal and Child Health Care Hospital, Xian Children's Hospital, People's Hospital of Guangxi, Henan Provincial People's Hospital, Guangdong Provincial People's Hospital, Shenzhen Bao'an Maternal and Child Health Hospital, Zhengzhou Children's Hospital | Pediatric Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation | 05/25 | 07/25 | | |
NCT06431360: Effect of Strontium-90 Brachytherapy Combined With Hyperthermia in the Treatment of Keloid |
|
|
| Recruiting | N/A | 80 | RoW | hyperthermia, heater | Nanjing First Hospital, Nanjing Medical University | Keloid | 05/25 | 06/25 | | |
NCT06431620: Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer |
|
|
| Recruiting | N/A | 15 | RoW | Recombinant Human Thyroid Stimulating Hormone | Nanjing First Hospital, Nanjing Medical University | Recombinant Human Thyroid Stimulating Hormone | 05/26 | 12/26 | | |
| Recruiting | N/A | 200 | RoW | antibiotic-impregnated catheter | Integra LifeSciences Corporation | Hydrocephalus | 07/26 | 12/26 | | |
NCT05867589: Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular Diseases |
|
|
| Recruiting | N/A | 100 | RoW | 68Ga/18F-FAPI-04 | Nanjing First Hospital, Nanjing Medical University | Myocardial Fibrosis | 12/25 | 12/25 | | |
| Recruiting | N/A | 300 | RoW | an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor | The First Affiliated Hospital of Zhengzhou University | Esophageal Neoplasms | 05/24 | 05/25 | | |
| Liu, Xiufeng |
| Active, not recruiting | 3 | 480 | RoW | KN035 plus Gemcitabine & oxaliplatin, Experimental, Gemcitabine & oxaliplatin, Active Comparator | 3D Medicines (Sichuan) Co., Ltd. | Biliary Tract Neoplasms | 01/25 | 01/25 | | |
